Blood:酪氨酸激酶Chk、Csk和磷酸酶PTPRJ相互作用调控血小板数量

2020-02-08 QQY MedSci原创

中心点:Chk、Csk和PTPRJ是血小板中SFKs的主要调节因子,在维持血小板计数中起关键作用。SFKs可通过磷酸化其激活环或C末端抑制酪氨酸残基来自动调节其活性。摘要:Src家族激酶(SFKs) Src、Lyn和Fyn对血小板活化均至关重要,还参与巨核细胞(MK)的发育和血小板的产生。血小板SFKs受C末端Src激酶(Csk)抑制,Csk可使C末端保守的酪氨酸残基磷酸化;SFKs还可被受体型酪

中心点:

Chk、Csk和PTPRJ是血小板中SFKs的主要调节因子,在维持血小板计数中起关键作用。

SFKs可通过磷酸化其激活环或C末端抑制酪氨酸残基来自动调节其活性。

摘要:

Src家族激酶(SFKs) Src、Lyn和Fyn对血小板活化均至关重要,还参与巨核细胞(MK)的发育和血小板的产生。血小板SFKs受C末端Src激酶(Csk)抑制,Csk可使C末端保守的酪氨酸残基磷酸化;SFKs还可被受体型酪氨酸磷酸酶PTPRJ (CD148, DEP1)激活,PTPRJ是使C末端保守的酪氨酸残基去磷酸化。

小鼠MK细胞缺失Csk和PTPRJ会增强SFK活性,但矛盾的是,由于负反馈机制(包括Csk同源激酶[Chk]表达上调),血小板的活性反而降低。

在本研究中,研究人员在小鼠模型中研究Chk在血小板中的作用、Chk与Csk的冗余功能以及废除Chk、Csk和PTPRJ所导致的生理后果。Chk敲除(KO)小鼠的血小板计数正常,Chk;Csk双敲(DKO)小鼠的血小板计数下降92%,在Chk;Csk;Ptprj三敲(TKO)小鼠中,血小板计数部分恢复。在DKO和TKO小鼠中,巨核细胞数量均显著增加。

在DKO血小板中,SFKs抑制酪氨酸的磷酸化几乎完全消失,而在TKO血小板中,Src和Fyn位点的磷酸化部分保留。这种残基磷酸化被Src抑制剂消除,揭示了一个意想不到的机制,即SFKs通过磷酸化其C末端酪氨酸残基来自动抑制其活性。

本研究表明SFKs抑制磷酸化的减少导致了血小板减少,Csk是血小板的主要抑制剂,Chk起辅助作用。除Chk和Csk外,PTPRJ缺失可改善血小板减少症的严重程度,提示靶向治疗可能在这种情况下发挥治疗效果。

原始出处:

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1909295, encodeId=fdc719092957c, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri May 15 23:57:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999172, encodeId=c32b19991e20f, content=<a href='/topic/show?id=ddba14864d1' target=_blank style='color:#2F92EE;'>#PTPRJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14864, encryptionId=ddba14864d1, topicName=PTPRJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Mon Mar 02 20:57:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1740670, encodeId=1bd81e4067001, content=<a href='/topic/show?id=fd0a95511dd' target=_blank style='color:#2F92EE;'>#酪氨酸激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95511, encryptionId=fd0a95511dd, topicName=酪氨酸激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22af34798690, createdName=luckyshitiancai_42705695, createdTime=Mon Mar 16 03:57:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777289, encodeId=a9731e77289cf, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Thu Jul 02 12:57:00 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471653, encodeId=248d14e1653a4, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Mon Feb 10 07:57:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496084, encodeId=06d51496084aa, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Mon Feb 10 07:57:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596047, encodeId=3300159604e3a, content=<a href='/topic/show?id=7b24e386455' target=_blank style='color:#2F92EE;'>#磷酸酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73864, encryptionId=7b24e386455, topicName=磷酸酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=584e18318123, createdName=andy2093, createdTime=Mon Feb 10 07:57:00 CST 2020, time=2020-02-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1909295, encodeId=fdc719092957c, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri May 15 23:57:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999172, encodeId=c32b19991e20f, content=<a href='/topic/show?id=ddba14864d1' target=_blank style='color:#2F92EE;'>#PTPRJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14864, encryptionId=ddba14864d1, topicName=PTPRJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Mon Mar 02 20:57:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1740670, encodeId=1bd81e4067001, content=<a href='/topic/show?id=fd0a95511dd' target=_blank style='color:#2F92EE;'>#酪氨酸激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95511, encryptionId=fd0a95511dd, topicName=酪氨酸激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22af34798690, createdName=luckyshitiancai_42705695, createdTime=Mon Mar 16 03:57:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777289, encodeId=a9731e77289cf, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Thu Jul 02 12:57:00 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471653, encodeId=248d14e1653a4, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Mon Feb 10 07:57:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496084, encodeId=06d51496084aa, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Mon Feb 10 07:57:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596047, encodeId=3300159604e3a, content=<a href='/topic/show?id=7b24e386455' target=_blank style='color:#2F92EE;'>#磷酸酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73864, encryptionId=7b24e386455, topicName=磷酸酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=584e18318123, createdName=andy2093, createdTime=Mon Feb 10 07:57:00 CST 2020, time=2020-02-10, status=1, ipAttribution=)]
    2020-03-02 hxzhang
  3. [GetPortalCommentsPageByObjectIdResponse(id=1909295, encodeId=fdc719092957c, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri May 15 23:57:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999172, encodeId=c32b19991e20f, content=<a href='/topic/show?id=ddba14864d1' target=_blank style='color:#2F92EE;'>#PTPRJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14864, encryptionId=ddba14864d1, topicName=PTPRJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Mon Mar 02 20:57:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1740670, encodeId=1bd81e4067001, content=<a href='/topic/show?id=fd0a95511dd' target=_blank style='color:#2F92EE;'>#酪氨酸激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95511, encryptionId=fd0a95511dd, topicName=酪氨酸激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22af34798690, createdName=luckyshitiancai_42705695, createdTime=Mon Mar 16 03:57:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777289, encodeId=a9731e77289cf, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Thu Jul 02 12:57:00 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471653, encodeId=248d14e1653a4, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Mon Feb 10 07:57:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496084, encodeId=06d51496084aa, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Mon Feb 10 07:57:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596047, encodeId=3300159604e3a, content=<a href='/topic/show?id=7b24e386455' target=_blank style='color:#2F92EE;'>#磷酸酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73864, encryptionId=7b24e386455, topicName=磷酸酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=584e18318123, createdName=andy2093, createdTime=Mon Feb 10 07:57:00 CST 2020, time=2020-02-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1909295, encodeId=fdc719092957c, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri May 15 23:57:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999172, encodeId=c32b19991e20f, content=<a href='/topic/show?id=ddba14864d1' target=_blank style='color:#2F92EE;'>#PTPRJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14864, encryptionId=ddba14864d1, topicName=PTPRJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Mon Mar 02 20:57:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1740670, encodeId=1bd81e4067001, content=<a href='/topic/show?id=fd0a95511dd' target=_blank style='color:#2F92EE;'>#酪氨酸激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95511, encryptionId=fd0a95511dd, topicName=酪氨酸激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22af34798690, createdName=luckyshitiancai_42705695, createdTime=Mon Mar 16 03:57:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777289, encodeId=a9731e77289cf, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Thu Jul 02 12:57:00 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471653, encodeId=248d14e1653a4, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Mon Feb 10 07:57:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496084, encodeId=06d51496084aa, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Mon Feb 10 07:57:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596047, encodeId=3300159604e3a, content=<a href='/topic/show?id=7b24e386455' target=_blank style='color:#2F92EE;'>#磷酸酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73864, encryptionId=7b24e386455, topicName=磷酸酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=584e18318123, createdName=andy2093, createdTime=Mon Feb 10 07:57:00 CST 2020, time=2020-02-10, status=1, ipAttribution=)]
    2020-07-02 FukaiBao
  5. [GetPortalCommentsPageByObjectIdResponse(id=1909295, encodeId=fdc719092957c, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri May 15 23:57:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999172, encodeId=c32b19991e20f, content=<a href='/topic/show?id=ddba14864d1' target=_blank style='color:#2F92EE;'>#PTPRJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14864, encryptionId=ddba14864d1, topicName=PTPRJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Mon Mar 02 20:57:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1740670, encodeId=1bd81e4067001, content=<a href='/topic/show?id=fd0a95511dd' target=_blank style='color:#2F92EE;'>#酪氨酸激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95511, encryptionId=fd0a95511dd, topicName=酪氨酸激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22af34798690, createdName=luckyshitiancai_42705695, createdTime=Mon Mar 16 03:57:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777289, encodeId=a9731e77289cf, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Thu Jul 02 12:57:00 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471653, encodeId=248d14e1653a4, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Mon Feb 10 07:57:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496084, encodeId=06d51496084aa, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Mon Feb 10 07:57:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596047, encodeId=3300159604e3a, content=<a href='/topic/show?id=7b24e386455' target=_blank style='color:#2F92EE;'>#磷酸酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73864, encryptionId=7b24e386455, topicName=磷酸酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=584e18318123, createdName=andy2093, createdTime=Mon Feb 10 07:57:00 CST 2020, time=2020-02-10, status=1, ipAttribution=)]
    2020-02-10 ylz8405
  6. [GetPortalCommentsPageByObjectIdResponse(id=1909295, encodeId=fdc719092957c, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri May 15 23:57:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999172, encodeId=c32b19991e20f, content=<a href='/topic/show?id=ddba14864d1' target=_blank style='color:#2F92EE;'>#PTPRJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14864, encryptionId=ddba14864d1, topicName=PTPRJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Mon Mar 02 20:57:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1740670, encodeId=1bd81e4067001, content=<a href='/topic/show?id=fd0a95511dd' target=_blank style='color:#2F92EE;'>#酪氨酸激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95511, encryptionId=fd0a95511dd, topicName=酪氨酸激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22af34798690, createdName=luckyshitiancai_42705695, createdTime=Mon Mar 16 03:57:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777289, encodeId=a9731e77289cf, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Thu Jul 02 12:57:00 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471653, encodeId=248d14e1653a4, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Mon Feb 10 07:57:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496084, encodeId=06d51496084aa, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Mon Feb 10 07:57:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596047, encodeId=3300159604e3a, content=<a href='/topic/show?id=7b24e386455' target=_blank style='color:#2F92EE;'>#磷酸酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73864, encryptionId=7b24e386455, topicName=磷酸酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=584e18318123, createdName=andy2093, createdTime=Mon Feb 10 07:57:00 CST 2020, time=2020-02-10, status=1, ipAttribution=)]
    2020-02-10 redcrab
  7. [GetPortalCommentsPageByObjectIdResponse(id=1909295, encodeId=fdc719092957c, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri May 15 23:57:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999172, encodeId=c32b19991e20f, content=<a href='/topic/show?id=ddba14864d1' target=_blank style='color:#2F92EE;'>#PTPRJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14864, encryptionId=ddba14864d1, topicName=PTPRJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Mon Mar 02 20:57:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1740670, encodeId=1bd81e4067001, content=<a href='/topic/show?id=fd0a95511dd' target=_blank style='color:#2F92EE;'>#酪氨酸激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95511, encryptionId=fd0a95511dd, topicName=酪氨酸激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22af34798690, createdName=luckyshitiancai_42705695, createdTime=Mon Mar 16 03:57:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777289, encodeId=a9731e77289cf, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Thu Jul 02 12:57:00 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471653, encodeId=248d14e1653a4, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Mon Feb 10 07:57:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496084, encodeId=06d51496084aa, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Mon Feb 10 07:57:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596047, encodeId=3300159604e3a, content=<a href='/topic/show?id=7b24e386455' target=_blank style='color:#2F92EE;'>#磷酸酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73864, encryptionId=7b24e386455, topicName=磷酸酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=584e18318123, createdName=andy2093, createdTime=Mon Feb 10 07:57:00 CST 2020, time=2020-02-10, status=1, ipAttribution=)]